Business
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin
About this update from Lonza Group Ag
[{"type":"text","content":"\nLonza Group AG / Key word(s): Half Year Results\n\nLonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook 23-Jul-2025 / 06:30 CET/CEST\n\nRelease of an ad hoc announcement pursuant to Art. 53 LR\n\nThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRIn H1 2025, Lonza delivered sales of CHF 3.6 billion with CER1 growth of 19.0% and CORE EBITDA of CHF 1.1 billion, resulting in a margin of 29.6% (+0.4ppts versus H1 2024)CDMO2 business delivered sales of CHF 3.1 billion with CER growth of 23.1% and CORE EBITDA of CHF 922 million, resulting in a margin of 30.2% (flat versus H1 2024)Sustained commercial momentum and high utilization levels in mammalian small-scale assetsCapsules & Health Ingredients (CHI) business on track for expected recovery with flat CER sales versus H1 2024 and a CORE EBITDA margin improvement of +1.4ppts to 26.2%CDMO Outlook for FY 2025 upgraded to CER sales growth of 20-21% (previously “approaching 20%”) and a CORE EBITDA margin of 30-31% (previously “approaching 30%”)CHI Outlook for FY 2025 confirmed at low-to-mid single-digit percentages CER sales growth and an improved CORE EBITDA margin in the mid-twenties Basel, Switzerland, 23 July 2025 – Lonza reported sales of CHF 3.6 billion in H1 2025, reflecting CER sales growth of 19.0% (17.0% AER3). CHF 1.1 billion CORE EBITDA resulted in a robust margin of 29.6% (+0.4ppts versus H1 2024). Including the contribution from the recently acquired Vacaville (US) site, the CDMO business delivered CER sales growth of 23.1% and a CORE EBITDA margin of 30.2% (flat versus H1 2024), supported by good operational execution, disciplined cost management and maturing growth projects. The CHI business continued to improve as expected, with flat sales versus H1 2024 (0.0% CER) and an improved CORE EBITDA margin of 26.2% (+1.4ppts versus H1 2024).CDMO sales in H1 benefited from an H1-weighted Vacaville performance and strong momentum in the Mammalian, Bioconjugates and Small Molecules Technology Platforms, with Bioscience returning to healthy growth. This positive momentum was partially offset by lower sales from Cell & Gene Technologies (CGT) and Microbial against a high comparison in H1 2024 and an H2-weighted delivery in 2025.\nFor Full-Year 2025, Lonza ove...